Bando E, Ji X, Kattan MW, et al. Development and validation of a pretreatment nomogram to predict overall survival in gastric cancer. Cancer Med. 2020;9:5708--5718. 10.1002/cam4.3225

**Funding information**

This work was not funded by research or departmental grants.

1. INTRODUCTION {#cam43225-sec-0005}
===============

To choose appropriate therapy and provide an estimation of prognosis, the American Joint Committee on Cancer (AJCC) has defined gastric cancer staging.[^1^](#cam43225-bib-0001){ref-type="ref"} AJCC staging is composed of three variables including tumor depth (T), nodal metastasis (N), and distant metastasis (M). However, other promising prognosticators, have been reported.[^2^](#cam43225-bib-0002){ref-type="ref"}, [^3^](#cam43225-bib-0003){ref-type="ref"}, [^4^](#cam43225-bib-0004){ref-type="ref"}

Nomograms have been developed to quantify risk by combining several prognostic factors in some malignancies.[^5^](#cam43225-bib-0005){ref-type="ref"}, [^6^](#cam43225-bib-0006){ref-type="ref"} We first developed a gastric cancer nomogram based on a Western database,[^7^](#cam43225-bib-0007){ref-type="ref"} followed by additional nomograms based on Asian databases.[^8^](#cam43225-bib-0008){ref-type="ref"}, [^9^](#cam43225-bib-0009){ref-type="ref"} All studies emphasizing nomograms have been more informative than those using AJCC staging. However, all previous gastric cancer nomograms were constructed using pathologic variables obtained after gastrectomy.

Selection of a treatment strategy is primarily based on the pretreatment clinical stage (cStage). Guidelines in Japan,[^10^](#cam43225-bib-0010){ref-type="ref"} the United States,[^11^](#cam43225-bib-0011){ref-type="ref"} and Europe[^12^](#cam43225-bib-0012){ref-type="ref"} state that the treatment strategy should be determined based on cStage. Furthermore, an increasing number of patients are undergoing neoadjuvant chemotherapy (NAC) in Western countries; therefore, the need for accurate assessment of cStage is vital. Studies demonstrating a significant correlation between cStage and survival have been reported recently.[^13^](#cam43225-bib-0013){ref-type="ref"}, [^14^](#cam43225-bib-0014){ref-type="ref"}

The AJCC has increasingly recognized the need for more personalized probabilistic predictions than those delivered by ordinal systems, particularly through the use of accurate risk assessment models.[^15^](#cam43225-bib-0015){ref-type="ref"} Despite this situation, there have been no published pretreatment gastric cancer nomograms constructed using pretreatment variables.

We therefore sought to develop the first pretreatment gastric cancer nomogram including the patients receiving nonsurgical therapy, with external validation in independent cohorts, to assist ongoing efforts toward a more personalized paradigm according to the AJCC Precision Medicine Core.

2. MATERIALS AND METHODS {#cam43225-sec-0006}
========================

2.1. Patients in developing cohort and pretreatment prognostic variables {#cam43225-sec-0007}
------------------------------------------------------------------------

Data registered in Shizuoka Cancer Center database were used in developing a nomogram. We enrolled 5231 patients with primary gastric cancer between October 2002 and July 2017.

We collected pretreatment information on patient demographics (age, sex, Eastern Cooperative Oncology Group Performance Status (ECOGPS)), and tumor characteristics (location, size, clinical depth (cT), number of positive regional nodes on CT (cN‐Number), location of positive nodes on CT (cN‐Location), liver metastasis, peritoneal dissemination, other sites of distant metastasis (cM), macroscopic type, histology (via endoscopic biopsy), serum carcinoembryonic antigen (CEA), and serum carbohydrate antigen 19‐9 (CA19‐9)) (see [Supporting Methods](#cam43225-sup-0001){ref-type="supplementary-material"} and Supporting Table [1](#cam43225-sup-0001){ref-type="supplementary-material"}).

This study was approved by the Institutional Review Board of Shizuoka Cancer Center (T29‐34‐29‐1, T30‐4‐30‐1).

2.2. Patients in external validation cohort {#cam43225-sec-0008}
-------------------------------------------

Two independent cohorts, including 1001 patients from Seoul St. Mary\'s Hospital (Seoul, Republic of Korea) and 389 patients from the University of Verona (Verona, Italy), formed external validation cohorts. These external validation cohorts of this study were approved by the Institutional Review Board of Seoul St. Mary\'s Hospital (KC17RESI0281) and the Italian Research Group for Gastric Cancer (GIRCG).

2.3. Statistical methods {#cam43225-sec-0009}
------------------------

Continuous variables were modeled as restricted cubic splines for potential nonlinear effect. Before modeling, we adopted log‐transformed CEA and CA19‐9 as predictors to reduce the skewness of the data. The endpoint in the nomogram was overall survival (OS). The nomogram was created with a Cox proportional hazard model, and it was validated internally and externally using measures of discrimination (Harrell\'s C‐index), calibration, and decision curve analysis (see [Supporting Statistical Methods](#cam43225-sup-0001){ref-type="supplementary-material"}). R version 3.4.4 (The R Foundation for Statistical Computing, Vienna, Austria) was used to perform all analyses.

3. RESULTS {#cam43225-sec-0010}
==========

3.1. Patient demography and treatment {#cam43225-sec-0011}
-------------------------------------

Descriptive statistics appear in Table [1](#cam43225-tbl-0001){ref-type="table"}. The therapeutic strategy was determined by the treatment guideline or protocol of participating clinical trials based on pretreatment tumor progression and patient condition. Treatments performed among study participants are summarized in Figure [1](#cam43225-fig-0001){ref-type="fig"}.

###### 

Patient characteristics and pretreatment clinical variables

  Pretreatment variables                                           
  ----------------------------------------------------- ---------- --------
  Location                                                         
  Lower (Antrum, Pylorus)                               1466       (28.0)
  Middle (Body)                                         2182       (41.7)
  Upper (Cardia, Fundus)                                1034       (19.8)
  Entire (Overlapping Stomach)                          432        (8.3)
  EGJ (Esophagogastric junction tumor)                  117        (2.2)
  Tumor Size (mm)                                                  
  Minimum                                               2          
  First quartile                                        28         
  Median                                                40         
  Mean                                                  52         
  Third quartile                                        70         
  Maximum                                               250        
  cT                                                               
  cT1a = Mucosa                                         1101       (21.0)
  cT1b = Submucosa                                      1227       (23.5)
  cT2 = Propria musclaris                               532        (10.2)
  cT3 = Subserosa                                       345        (6.6)
  cT4a = Serosal invasion                               1809       (34.6)
  cT4b = Adjacent organ involvement                     217        (4.1)
  cN (Number)                                                      
  Minimum                                               0          
  First quartile                                        0          
  Median                                                0          
  Mean                                                  2.1        
  Third quartile                                        3          
  Maximum                                               42         
  cN (Location)                                                    
  cN0                                                   3398       (65.0)
  cN1 (Perigastric or No. 110 if EGJ)                   922        (17.6)
  cN2a (No. 7, 8a, 9)                                   377        (7.2)
  cN2b (No 10, 11p, 11d, 12a or 19, 20, 111 if EGJ)     95         (1.8)
  cNM (Nonregional LN, intra‐abdominal)                 439        (8.4)
  Liver metastasis                                                 
  Negative                                              4889       (93.5)
  Solitary                                              41         (0.8)
  Multiple                                              301        (5.8)
  Peritoneum                                                       
  Negative                                              4861       (92.9)
  Positive                                              370        (7.1)
  cM                                                               
  Negative                                              5103       (97.6)
  Positive                                              128        (2.4)
  Macroscopic type                                                 
  Type 0                                                2670       (51.0)
  Type 1                                                169        (3.2)
  Type 2                                                830        (15.9)
  Type 3                                                1088       (20.8)
  Type 4                                                474        (9.1)
  Histology                                                        
  G1 (Well‐differentiated type)                         877        (16.8)
  G2 (Moderately differentiated type)                   1226       (23.4)
  G3 (Poorly differentiated or Undifferentiated type)   3128       (59.8)
  Age                                                              
  Minimum                                               19         
  First quartile                                        60         
  Median                                                67         
  Mean                                                  66         
  Third quartile                                        74         
  Maximum                                               95         
  Sex                                                              
  Female                                                1644       (31.4)
  Male                                                  3587       (68.6)
  ECOG Performance Status (PS)                                     
  0                                                     4360       (83.3)
  1                                                     611        (11.7)
  2                                                     198        (3.8)
  3 or 4                                                62         (1.2)
  Serum CEA (ng/mL)                                                
  Minimum                                               0.5        
  First quartile                                        1.4        
  Median                                                2.3        
  Mean                                                  46.8       
  Third quartile                                        4.0        
  Maximum                                               38 640.0   
  Serum CA19‐9 (U/mL)                                              
  Minimum                                               2          
  First quartile                                        3          
  Median                                                8          
  Mean                                                  637        
  Third quartile                                        18         
  Maximum                                               708 200    

cM excludes liver, peritoneum, intra‐abdominal nonregional metastasis.
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![Summary of treatment performed after diagnosis. Abbreviations: BSC, best supportive care; NAC, neoadjuvant chemotherapy](CAM4-9-5708-g001){#cam43225-fig-0001}

3.2. Survival outcomes {#cam43225-sec-0012}
----------------------

Figure [2](#cam43225-fig-0002){ref-type="fig"} shows OS curves according to AJCC cStage. From the step‐down model reduction method, all 15 variables were selected to construct the nomogram for OS (Table [2](#cam43225-tbl-0002){ref-type="table"}). This nomogram can be used to predict probability of patient death due to any cause at 1, 3, and 5 years

. The equation predicting 5‐year OS is presented (see [Supporting Result](#cam43225-sup-0001){ref-type="supplementary-material"}).

![Kaplan‐Meier survival curves of overall survival by American Joint Committee on Cancer stage (AJCC) grouping in developing cohort, with numbers at risk](CAM4-9-5708-g002){#cam43225-fig-0002}

###### 

Multivariable Cox proportional hazards model of pretreatment variables for overall survival

  Pretreatment variables   Chi‐Square   *P*      HR     95% CI
  ------------------------ ------------ -------- ------ ------------
  Location                 11.62        .020            
  Lower                                          1.18   1.04\~1.34
  Middle                                         1      
  Upper                                          1.20   1.04\~1.37
  Entire                                         1.24   1.03\~1.50
  EGJ                                            1.31   1.03\~1.66
  Tumor size (mm)          1.79         .181            
                                                 1.06   0.97\~1.16
  cT                       79.20        \<.001          
  cT1a                                           0.24   0.17\~0.34
  cT1b                                           0.30   0.21\~0.42
  cT2                                            0.43   0.33\~0.55
  cT3                                            0.62   0.51\~0.76
  cT4a                                           1      
  cT4b                                           1.13   0.96\~1.33
  cN (Number)              19.15        \<.001   1.08   
                                                        1.04\~1.12
  cN (Location)            38.81        \<.001          
  cN0                                            1      
  cN1                                            1.20   1.05\~1.38
  cN2a                                           1.28   1.07\~1.53
  cN2b                                           1.96   1.47\~2.57
  cNM                                            1.82   1.48\~2.24
  Liver Metastasis         73.04        \<.001          
  Negative                                       1      
  Solitary                                       1.69   1.18\~2.42
  Multiple                                       2.02   1.71\~2.39
  Peritoneum               83.82        \<.001          
  Negative                                       1      
  Positive                                       1.98   1.71\~2.30
  cM                       6.07         .014            
  Negative                                       1      
  Positive                                       1.30   1.05\~1.60
  Macroscopic type         82.43        \<.001          
  Type 0                                         1      
  Type 1                                         1.62   1.16\~2.27
  Type 2                                         1.01   0.75\~1.36
  Type 3                                         1.30   0.97\~1.73
  Type 4                                         2.30   1.67\~3.16
  Histology                24.94        \<.001          
  G1                                             0.73   0.62\~0.86
  G2                                             0.79   0.70\~0.88
  G3                                             1      
  Age                      44.79        \<.001          
                                                 1.50   1.40\~1.61
  Sex                      1.08         .299            
  Female                                         0.95   0.85\~1.05
  Male                                           1      
  ECOG PS                  86.92        \<.001          
  0                                              1      
  1                                              1.45   1.27\~1.66
  2                                              2.10   1.74\~2.53
  3 or 4                                         2.44   1.82\~3.26
  Serum CEA (ng/mL)        6.10         .014            
                                                 1.15   1.07\~1.25
  Serum CA19‐9 (U/mL)      5.72         .017            
                                                 1.06   1.01\~1.10

Abbreviations: CI, confidence interval; HR, hazard ratio.

John Wiley & Sons, Ltd

![Pretreatment gastric cancer nomogram. This nomogram provides a method to calculate 1‐, 3‐, and 5‐y probability of survival. Add the scores for each covariate together and locate the total score on the total points axis. Draw a line straight down to the 1‐, 3‐, and 5‐y OS axes to obtain the probability. Abbreviations: CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; cM, distant metastasis except metastasis in intra‐abdominal nonregional lymph node, liver metastasis, and peritoneal dissemination; ECOGPS, Eastern Cooperative Oncology Group performance status; Liver, liver metastasis; ln, natural logarithm; OS, overall survival; Peritoneum, peritoneal dissemination.](CAM4-9-5708-g003){#cam43225-fig-0003}

3.3. Evaluation of nomogram in the developing cohort {#cam43225-sec-0013}
----------------------------------------------------

The C‐index for the model was 0.855 (95% CI, 0.848‐0.863); that of the AJCC was 0.819 (95% CI, 0.810‐0.828). The calibration appeared to be accurate for predicting 5‐year OS (Figure [4A](#cam43225-fig-0004){ref-type="fig"}). Figure [4B](#cam43225-fig-0004){ref-type="fig"} shows the results of decision curve analysis. Compared with scenarios where no prediction model was used for a pretreatment decision (ie, treat all or treat none), the nomogram had a favorable net benefit across a wide range of decision threshold probabilities, between approximately 15% and 90% OS at 5 years. Note the heterogeneity in nomogram‐predicted probability present within AJCC stages (Figure [4C](#cam43225-fig-0004){ref-type="fig"}).

![Discriminatory performance of the nomogram. Data are from the development cohort. A, Calibration plot of the overall survival nomogram. B, Decision curve to plot the net benefit achieved by making clinical decisions based on the final multivariable model prediction at 5 y, for overall survival. C, Distribution of nomogram predictions within each American Joint Committee on Cancer (AJCC) stage grouping, for overall survival](CAM4-9-5708-g004){#cam43225-fig-0004}

3.4. Evaluation of nomogram in the external validation cohort {#cam43225-sec-0014}
-------------------------------------------------------------

The OS curve of the Seoul St. Mary\'s cohort according to the latest AJCC cStage and the OS curve of the Verona cohort according to AJCC cStage are presented (see Supporting Figure [1](#cam43225-sup-0001){ref-type="supplementary-material"}A, B). In external validation of the Seoul St. Mary\'s cohort, the C‐index applied to the nomogram was 0.856 (95% CI, 0.823‐0.879), compared with 0.795 (95% CI, 0.776‐0.814) when applied to the AJCC. In external validation of the Verona cohort, the C‐index applied to the nomogram was 0.714 (95% CI, 0.681‐0.746), compared with 0.648 (95% CI, 0.629‐0.667) applied to the AJCC. The predicted and observed outcomes were in good agreement (see Supporting Figure [2](#cam43225-sup-0001){ref-type="supplementary-material"}A, B). This pretreatment nomogram also yielded a wide range of clinical net benefit in external cohorts (see Supporting Figure [3](#cam43225-sup-0001){ref-type="supplementary-material"}A, B).

3.5. Additional analysis {#cam43225-sec-0015}
------------------------

In addition, a stage‐specific subset survival analysis of the three risk groups calculated using the nomogram was performed. The definition of three risk group were below: low‐risk group, nomogram‐predicted 5‐year survival rate (5‐years) is 70‐100%, intermediate‐risk group, nomogram‐predicted 5‐years is 30‐70%, and high‐risk group, nomogram‐predicted 5‐years is 0‐30%. The rationale for using three risk groups and their cutoff values is based on survival outcomes stratified AJCC clinical staging that decides therapeutic planning for gastric cancer (see Supporting Table 2).

The intermediate‐risk group had a significantly poorer survival than the low‐risk group in cStage I/IIA (*P* \< .001) and cStage IIB/III (*P* \< .001) (Figure [5](#cam43225-fig-0005){ref-type="fig"}A,B). The high‐risk group had a significantly poorer survival than the intermediate‐risk group in cStage IIB/III (*P* \< .001) and cStage IVA/IVB (*P* \< .001) (Figure [5](#cam43225-fig-0005){ref-type="fig"}B,C). There may be a possibility that 102 patients in cStage I/IIA (3.6%) and 391 (26.9%) patients in cStage IIB/III have been undertreated, and 160 patients (11.0%) in cStage IIB/III have been unnecessarily overtreated. In addition, the AJCC staging system lost its predictive ability in each nomogram‐predicted risk group (see Supporting Figure [4](#cam43225-sup-0001){ref-type="supplementary-material"}A‐C), except for cStage IVB. We also performed these analyses on external validation cohorts. Clear survival distributions were found in the same AJCC stage in both cohorts (see Supporting Figures [5](#cam43225-sup-0001){ref-type="supplementary-material"}A, B and [6](#cam43225-sup-0001){ref-type="supplementary-material"}A‐C). In the reverse analysis in both external cohorts, the AJCC staging system lost its predictive ability in each risk group (see Supporting Figures [7](#cam43225-sup-0001){ref-type="supplementary-material"}A‐C and [8](#cam43225-sup-0001){ref-type="supplementary-material"}A‐C).

![Kaplan‐Meier survival curves of the overall survival of patients stratified into three risk groups according to nomogram‐predicted 5‐y survival rate in the development cohort, with the numbers at risk. A, cStage I/ IIA, B, cStage IIB/III, and C, cStage IVA/IVB](CAM4-9-5708-g005){#cam43225-fig-0005}

4. DISCUSSION {#cam43225-sec-0016}
=============

To our best knowledge, this is the first study to build a gastric cancer nomogram using only pretreatment clinical variables and including not only patients receiving initial surgery, but also those receiving NAC, chemotherapy, or BSC. Part of our data,[^16^](#cam43225-bib-0016){ref-type="ref"} as well as that of the National Cancer Data Base (NCDB) in the United States,[^14^](#cam43225-bib-0014){ref-type="ref"} was used for constructing the cStage of the latest edition of the AJCC.[^1^](#cam43225-bib-0001){ref-type="ref"}

This study has several strengths. First, new nomogram was successfully validated internally and externally in two independent cohorts, not only with the C‐index or calibration plots but also decision curve analysis. Decision curve analyses assess the clinical usefulness of prediction tools by quantifying the net benefits when different threshold probabilities are considered. Thresholds are attractive for use in clinical trials. In internal validation, for example, if the inclusion criteria for a neoadjuvant clinical trial is more than 30% the risk for OS at 5 years, a nomogram‐based decision would have a net benefit of approximately 0.17, which is 0.17 greater than assuming all patients need treatment. In other words, use of the nomogram would lead to the equivalent of 17% reduction in unnecessary treatment without a decrease in the number of patients who duly need treatment.

Second, our study showed the clear survival distributions according to the nomogram‐based risk groups in the stage‐specific evaluation both in developing and external cohorts. In addition, the AJCC staging system lost its predictive ability in each nomogram‐predicted risk group. These results indicate that some patients of the intermediate‐risk group (cStage IIB/III) are actually at a high or low risk, and some patients in the low‐risk group (cStage I/IIA) are actually at an intermediate risk. We are convinced that the use of the nomogram prediction could aid in avoiding undertreatment or unnecessary overtreatment for a large number of patients in routine practice. For example, NAC is the standard treatment for an advanced gastric cancer in Western countries such as Italy. Even for a cStage I cancer, patients in the intermediate‐ or high‐risk groups become candidates for NAC according to the nomogram prediction. Conversely, for cStage III cancer, the low‐risk group could avoid NAC. A variety of treatments can be planned for the patients in stage IV of the disease. These will greatly depend on the patient\'s condition and the metastasis status. Therefore, it is difficult to assess if the performed treatment was accurate, or an overtreatment was performed. Nonetheless, the patients in the high‐risk group had significantly poorer outcomes than those in the intermediate‐risk group. Therefore, the nomogram may be useful for treatment selection even in cStageIV. In addition, we believe that nomogram prediction plays a vital role not only in the choice of accurate therapy in practice, but also in patient recruitment/enrichment for prospective clinical trials. For patients with cStage III gastric cancer, the standard therapy was initial surgery in Japan and Korea. In recent years, however, a clinical trial of NAC is ongoing in both countries. Using nomograms to define eligibility is expected to allow truly intermediate/high‐risk patients to enter the trial, while excluding patients who are not of sufficient risk relative to high‐risk patients in the traditional sense. Weiser et al. suggested that nomograms would considerably reduce the sample size requirement, which could reduce operation time and cost.[^17^](#cam43225-bib-0017){ref-type="ref"}

Third, this nomogram was constructed using pretreatment factors, which are recommended to collect and register by the AJCC and Union for International Cancer Control (UICC). For establishing a statistical risk assessment model as a future staging system, the AJCC presents the recommended pretreatment variables in the Cancer Staging Manual,[^1^](#cam43225-bib-0001){ref-type="ref"} such as tumor location, tumor size, location of clinical positive nodes, sites of distant metastasis, serum CEA, and serum CA19‐9, in parallel with traditional factors including depth of invasion (cT) and number of clinically malignant nodes (cN). The eighth UICC TNM classification includes age as a host‐related prognostic factor.[^18^](#cam43225-bib-0018){ref-type="ref"} We also included sex, histology, macroscopic type, and ECOG‐PS.

Inclusion of 15 variables seems complex; however, these variables can be collected easily, even in general hospitals. Recent advancements in computer technologies provide easy ways to use online software. With use of online calculator, some cumbersome problems could be solved. Some prediction models are open access on the Cleveland Clinic website (<http://riskcalc.org/>).[^19^](#cam43225-bib-0019){ref-type="ref"}

Previous studies have reported better survival outcomes in Asian patients than Western patients.[^20^](#cam43225-bib-0020){ref-type="ref"}, [^21^](#cam43225-bib-0021){ref-type="ref"} Consistent with these findings, our results for calibration plots in external validation of the Verona (Italy) cohort were favorable. Recent studies report that survival does not differ significantly between Asian and Western patients when comparing similar subtypes of gastric cancer[^22^](#cam43225-bib-0022){ref-type="ref"} or when adjusting by Han\'s Korean nomogram.[^23^](#cam43225-bib-0023){ref-type="ref"} These studies speculate that gastric cancer is a heterogeneous disease and when adjusted by many variables, the difference in survival outcome between Asian and Western patients may disappear.

The present study has several limitations. Although we constructed a novel risk model, its predictive accuracy can be improved. Another limitation is that the two external validation cohorts were based on surgical databases. The St. Mary\'s cohort included patients with potentially good outcomes because they were treated with preoperative curative intent followed by curative gastrectomy. Even in cStage I/II/III patients treated with curative intent, quite a few patients had incurable factors.[^13^](#cam43225-bib-0013){ref-type="ref"} The Verona cohort included some cStageIV patients; however, surgery was also assumed. One feature of our nomogram is that it can predict the treatment outcomes of nonsurgical as well as resected cases; however, these variations might cause some biases.

In conclusion, the newly developed gastric cancer pretreatment nomogram will be useful for planning clinical trial designs, selecting appropriate therapy, and for patient counseling in routine practice. This model will improve on the traditional AJCC system in the future.
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